Bio-Path Holdings, Inc. BPTH shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.
The Details:
BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Bio-Path said BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
“We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration (FDA) to review patient study data,” said Peter Nielsen, CEO of Bio-Path Holdings.
“Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options,” Nielsen added.
Bio-Path shares are moving on heavy trading volume Thursday and have been halted for volatility. According to data from Benzinga Pro, more than 40 million shares have already been traded in the session, compared to the stock’s 100-day average of less than 39,000 shares.
Related News: What’s Going On With Arm Holdings Stock?
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Bio-Path’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
BPTH Price Action: According to Benzinga Pro, Bio-Path shares are up 67% at $5.41 at the time of publication Thursday.
Image: Phoenix Locklear from Pixabay
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
